Osteoporosis: prevention and treatment

被引：0

作者：

Tkaczuk-Wlach, Joanna ^{[1
]}

Sobstyl, Malgorzata ^{[1
]}

Jakiel, Grzegorz ^{[2
]}

机构：

[1] Uniwersytet Med Lublinie, Katedra & Klin Ginekol & Endokrynol Ginekol, Lublin, Poland

[2] CMKP Warszawie, Klin Poloznictwa & Ginekol, Warsaw, Poland

来源：

MENOPAUSE REVIEW-PRZEGLAD MENOPAUZALNY | 2010年 / 9卷 / 04期

关键词：

osteoporosis; diagnosis of osteoporosis; prevention; treatment; FRACTURE RISK REDUCTION; POSTMENOPAUSAL WOMEN; VERTEBRAL FRACTURE; STRONTIUM RANELATE; SALMON-CALCITONIN; MULTIPLE OUTCOMES; WEIGHT-LOSS; BONE LOSS; RALOXIFENE; RISEDRONATE;

D O I：

暂无

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

The aim of the osteoporosis management is to reduce the risk of fracture. The primary clinical goal is to identify patients at high risk of fracture rather than to identify men or women with osteoporosis. This article summarizes current knowledge about effective prevention and treatment of osteoporosis.

引用

页码：283 / 287

页数：5

共 32 条

[1] Raloxifene and cardiovascular events in osteoporotic postmenopausal women - Four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial [J].

Barrett-Connor, E ;

Grady, D ;

Sashegyi, A ;

Anderson, PW ;

Cox, DA ;

Hoszowski, K ;

Rautaharju, P ;

Harper, KD .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (07) :847-857

[2] Oral bioavailability and bone-sparing effects of estetrol in an osteoporosis model [J].

Bennink, H. J. T. Coelingh ;

Heegaard, A. -M. ;

Visser, M. ;

Holinka, C. F. ;

Christiansen, C. .

CLIMACTERIC, 2008, 11 :2-14

[3]

BINGHAMWRIGHT JC, 2007, RHEUMATOLOGY, V46, P257

[4] Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial [J].

Black, DM ;

Thompson, DE ;

Bauer, DC ;

Ensrud, K ;

Musliner, T ;

Hochberg, MC ;

Nevitt, MC ;

Suryawanshi, S ;

Cummings, SR .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (11) :4118-4124

[5]

BLAU LA, 2000, J CLIN ENDOCR METAB, V85, P720

[6]

Bonnick SL, 2010, MENOPAUSE, V17, P25, DOI [10.1097/gme.0b013e3181e617e6, 10.1097/gme.0b013e3181c617e6]

[7] A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study [J].

Chesnut, CH ;

Silverman, S ;

Andriano, K ;

Genant, H ;

Gimona, A ;

Harris, S ;

Kiel, D ;

LeBoff, M ;

Maricic, M ;

Miller, P ;

Moniz, C ;

Peacock, M ;

Richardson, P ;

Watts, N ;

Baylink, D .

AMERICAN JOURNAL OF MEDICINE, 2000, 109 (04) :267-276

[8] Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial [J].

Delmas, PD ;

Ensrud, KE ;

Adachi, JD ;

Harper, KD ;

Sarkar, S ;

Gennari, C ;

Reginster, JY ;

Pols, HAP ;

Recker, RR ;

Harris, ST ;

Wu, WT ;

Genant, HK ;

Black, DM ;

Eastell, R .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (08) :3609-3617

[9] Intentional and unintentional weight loss increase bone loss and hip fracture risk in older women [J].

Ensrud, KE ;

Ewing, SK ;

Stone, KL ;

Cauley, JA ;

Bowman, PJ ;

Cummings, SR .

JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2003, 51 (12) :1740-1747

[10]

Ervin R Bethene, 2004, Adv Data, P1

← 1 2 3 4 →